BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12152684)

  • 1. Altering heparin cofactor II at VAL439 (P6) either impairs inhibition of thrombin or confers elastase resistance.
    Cunningham MA; Bhakta V; Sheffield WP
    Thromb Haemost; 2002 Jul; 88(1):89-97. PubMed ID: 12152684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
    Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
    Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II.
    Sutherland JS; Bhakta V; Sheffield WP
    Thromb Res; 2006; 117(4):447-61. PubMed ID: 15869786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition.
    Sutherland JS; Bhakta V; Filion ML; Sheffield WP
    Biochemistry; 2006 Sep; 45(38):11444-52. PubMed ID: 16981704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
    Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate.
    Ben Mansour M; Dhahri M; VĂ©nisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM
    Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand binding to thrombin exosite II induces dissociation of the thrombin-heparin cofactor II(L444R) complex.
    Han JH; Tollefsen DM
    Biochemistry; 1998 Mar; 37(9):3203-9. PubMed ID: 9485475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
    Sutherland JS; Bhakta V; Sheffield WP
    Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin cofactor II is more sensitive than antithrombin to secretory impairment arising from mutations introduced into its carboxy-terminal region.
    Bhakta V; Begbie ME; Gupta A; Sandhu V; Sheffield WP
    Thromb Res; 2004; 113(2):163-73. PubMed ID: 15115672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
    Van Deerlin VM; Tollefsen DM
    J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex.
    Maekawa H; Sato H; Tollefsen DM
    Thromb Res; 2000 Dec; 100(5):443-51. PubMed ID: 11150588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.
    Boyle AJ; Roddick LA; Bhakta V; Lambourne MD; Junop MS; Liaw PC; Weitz JI; Sheffield WP
    BMC Biochem; 2013 Mar; 14():6. PubMed ID: 23496873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition.
    Ciaccia AV; Monroe DM; Church FC
    J Biol Chem; 1997 May; 272(22):14074-9. PubMed ID: 9162031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of frog and chicken cDNAs encoding heparin cofactor II.
    Colwell NS; Tollefsen DM
    Thromb Haemost; 1998 Nov; 80(5):784-90. PubMed ID: 9843172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition.
    Hayakawa Y; Hirashima Y; Kurimoto M; Hayashi N; Hamada H; Kuwayama N; Endo S
    FEBS Lett; 2002 Jul; 522(1-3):147-50. PubMed ID: 12095635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of recombinant heparin cofactor II expressed in insect cells.
    Ciaccia AV; Cunningham EL; Church FC
    Protein Expr Purif; 1995 Dec; 6(6):806-12. PubMed ID: 8746633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the proposed serpin-enzyme complex receptor recognition site in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes.
    Maekawa H; Tollefsen DM
    J Biol Chem; 1996 Aug; 271(31):18604-9. PubMed ID: 8702511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of heparin cofactor II anticoagulant activity.
    Bauman SJ; Church FC
    J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role].
    Rossi EB; Duboscq CL; Kordich LC
    Medicina (B Aires); 1999; 59(1):95-104. PubMed ID: 10349131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.
    Cooper ST; Rezaie AR; Esmon CT; Church FC
    Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.